search
Back to results

Targeting Abdominal Perfusion Pressure in Septic Shock (MAP-APP)

Primary Purpose

Acute Kidney Injury, Septic Shock, Resuscitations

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Abdominal Perfusion Pressure (APP)
Mean Arterial Pressure (MAP)
Sponsored by
Potrero Medical
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Kidney Injury

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Adult (age ≥ 18)
  2. Septic shock - identified as early as possible as evidenced by:

    1. Clinical diagnosis of sepsis defined as documented or suspected infection with the use of antibiotic administration OR
    2. Meets qSOFA (Quick Sequential Organ Failure Assessment) Criteria per the Sepsis-3 definitions:

    i. Respiratory rate ≥ 22/min ii. Altered mentation iii. Systolic blood pressure ≤ 100 mmHg AND c. Shock dependent on vasopressor therapy following initial 12-hour Resuscitation Period refractory to further volume expansion as assessed by clinical treatment team; this may be supported by either: i. Lack of blood pressure response following fluid bolus or passive leg raise ii. Hemodynamic data as available (e.g. PPV [positive pressure ventilation], SVV [stroke volume variation], echo, PAOP [pulmonary artery occlusion pressure], right-heart catheterization, etc.)

  3. Indication for a urinary bladder catheter (or one currently in place)
  4. Indication for an arterial line (or one currently in place at any site)

FOR MONITORING PHASE OF STUDY (MONITORING GROUP)

  1. All of the above criteria for the Resuscitation and Observational Periods of the study
  2. Intra-abdominal pressure < 8 mmHg

FOR INTERVENTION PHASE OF STUDY (APP VS MAP GROUPS)

  1. All of the above criteria for the Resuscitation and Observational Periods of the study
  2. Intra-abdominal pressure ≥ 8 mmHg

Exclusion Criteria:

  1. Inability to receive a urinary bladder catheter
  2. Chronic suprapubic catheter in place
  3. Cirrhosis/end stage liver disease, including Child-Pugh class C
  4. Severe AKI [acute kidney injury] as defined by life-threatening electrolyte, acidemia, or other indication for imminent emergent dialysis needs within 12 hours of hospital admission
  5. Evidence of chronic renal failure stage 5 (including serum creatinine values consistent with CKD 5 [chronic kidney disease, stage 5] or dialysis dependence) in 12-months prior to enrollment
  6. Active gastrointestinal bleed likely causing/contributing to the hemodynamic instability
  7. Acute intra-abdominal trauma (including intraabdominal surgery within the prior 30 days)
  8. Acute pancreatitis with no established source of infection
  9. Treating physician deems aggressive care is unsuitable, or has decided to de-escalate care [Do Not Resuscitate (DNR) patients receiving standard care are still eligible]
  10. In the opinion of the treating attending physician the patient is unsuitable for the study for any legitimate reason including lack of equipoise, anticipated imminent significant deterioration, anticipated imminent recovery, incarceration, pre-existing medical or psychiatric condition that treating attending physician deems not appropriate for study, or interfering medications
  11. Known previous or concurrent enrollment in a treatment clinical trial that, in the opinion of the investigator, might interfere with the objectives/endpoints of this clinical trial
  12. Known contraindication to bladder pressure measurement
  13. Known pregnancy
  14. Suspected or known increased intracranial pressure requiring active neurosurgical consultation
  15. Cardiogenic shock requiring extracorporeal support
  16. Any requirement for chest compressions prior to enrollment

Sites / Locations

  • Central Arkansas Veterans Healthcare System
  • University of Arkansas Medical Center
  • Grady Memorial Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

No Intervention

Active Comparator

Experimental

Arm Label

Monitoring Group

Mean Arterial Pressure (MAP) Group

Abdominal Perfusion Pressure (APP) Group

Arm Description

Patients that sustain intra-abdominal pressure of < 8 mmHg for 48 hours from sepsis diagnosis. Patients will be monitored and given sepsis standard of care.

Patients with elevated intra-abdominal pressure of ≥ 8 mmHg for 48 hours from sepsis diagnosis.

Patients with elevated intra-abdominal pressure of ≥ 8 mmHg for 48 hours from sepsis diagnosis.

Outcomes

Primary Outcome Measures

Study kidney function by controlling MAP targets to maintain APP levels, in critically ill patients with septic shock and elevated IAP.
To study kidney function and recovery in patients with septic shock and elevated IAP as measured by timed creatinine clearance on calendar days 1-7 when targeting treatment to maintain APP ≥ 60 mmHg with a variable MAP target as compared to standard of care with a fixed MAP target. Creatinine clearance on calendar day 7 post-intervention or on day of ICU discharge, whichever is earliest, is the primary endpoint. Post hospital stay, subjects will have 30 day and 90 day follow up to check subject health status.

Secondary Outcome Measures

Study AKI by controlling MAP targets to maintain APP levels, in patients with IAH treated with standard of care versus patients with septic shock without IAH.
To study the incidence, progression and recovery of AKI as well as patient-centered outcomes among patients with IAH treated by APP target versus standard of care. To study renal injury and recovery and patient-centered outcomes among septic shock patients without IAH.

Full Information

First Posted
June 27, 2018
Last Updated
January 11, 2021
Sponsor
Potrero Medical
Collaborators
Emory University, University of Arkansas, Central Arkansas Veterans Healthcare System
search

1. Study Identification

Unique Protocol Identification Number
NCT03582046
Brief Title
Targeting Abdominal Perfusion Pressure in Septic Shock
Acronym
MAP-APP
Official Title
Targeting Abdominal Perfusion Pressure in Septic Shock (The MAP APP Study)
Study Type
Interventional

2. Study Status

Record Verification Date
January 2021
Overall Recruitment Status
Terminated
Why Stopped
Lack of Enrollment
Study Start Date
February 5, 2019 (Actual)
Primary Completion Date
February 27, 2020 (Actual)
Study Completion Date
June 20, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Potrero Medical
Collaborators
Emory University, University of Arkansas, Central Arkansas Veterans Healthcare System

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A randomized control trial among patients with septic shock, studying the incidence, progression and recovery of AKI.
Detailed Description
Intra-abdominal pressure (IAP) has proven to be an important physiologic parameter in critically ill patients, and elevated IAP can lead to intra-abdominal hypertension (IAH). Literature suggests that IAH is common in patients with septic shock and that there is an association between the presence of IAH and acute kidney injury (AKI) in this group. Mean arterial pressure (MAP) and IAP together help determine the abdominal perfusion pressure (APP) of organs and tissues within the abdominal cavity. Current clinical guidelines for septic shock encourage targeting MAP of 65-70 mmHg with the use of vasopressors after volume resuscitation. However, it remains unclear if hemodynamic support targeting APP: (a) reduces development of acute kidney injury (AKI), (b) decreases progression of AKI, or (c) improves renal recovery rate compared to standard care for severe septic shock patients. A novel Foley catheter and monitoring device, the Accuryn Monitoring System, is capable of detecting physiologic changes in temperature, urine output (UO) and intra-abdominal pressure (IAP). These data streams are captured continuously by a device that is minimally invasive and at a high frequency which, in combination with MAP, allow for a simple calculation of abdominal perfusion pressure (APP). The purpose of this study is to assess kidney function and recovery in septic shock patients and elevated IAP when targeting treatment to maintain APP ≥ 60 mmHg as compared to standard of care targeting MAP of 65-70 mmHg.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Kidney Injury, Septic Shock, Resuscitations

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Monitoring Group
Arm Type
No Intervention
Arm Description
Patients that sustain intra-abdominal pressure of < 8 mmHg for 48 hours from sepsis diagnosis. Patients will be monitored and given sepsis standard of care.
Arm Title
Mean Arterial Pressure (MAP) Group
Arm Type
Active Comparator
Arm Description
Patients with elevated intra-abdominal pressure of ≥ 8 mmHg for 48 hours from sepsis diagnosis.
Arm Title
Abdominal Perfusion Pressure (APP) Group
Arm Type
Experimental
Arm Description
Patients with elevated intra-abdominal pressure of ≥ 8 mmHg for 48 hours from sepsis diagnosis.
Intervention Type
Device
Intervention Name(s)
Abdominal Perfusion Pressure (APP)
Other Intervention Name(s)
Intra-Abdominal Pressure (IAP)
Intervention Description
Intra-abdominal Pressure (IAP) actively measured and recorded every four hours, and mean arterial pressure (MAP) adjusted to maintain abdominal perfusion pressure (APP) levels ≥ 60 mmHg.
Intervention Type
Device
Intervention Name(s)
Mean Arterial Pressure (MAP)
Intervention Description
Intra-abdominal Pressure (IAP) recorded passively in device, but not measured or reviewed by physician. Patient will be treated with sepsis standard of care, maintaining mean arterial pressure (MAP) of ≥ 65 mmHg.
Primary Outcome Measure Information:
Title
Study kidney function by controlling MAP targets to maintain APP levels, in critically ill patients with septic shock and elevated IAP.
Description
To study kidney function and recovery in patients with septic shock and elevated IAP as measured by timed creatinine clearance on calendar days 1-7 when targeting treatment to maintain APP ≥ 60 mmHg with a variable MAP target as compared to standard of care with a fixed MAP target. Creatinine clearance on calendar day 7 post-intervention or on day of ICU discharge, whichever is earliest, is the primary endpoint. Post hospital stay, subjects will have 30 day and 90 day follow up to check subject health status.
Time Frame
90 days
Secondary Outcome Measure Information:
Title
Study AKI by controlling MAP targets to maintain APP levels, in patients with IAH treated with standard of care versus patients with septic shock without IAH.
Description
To study the incidence, progression and recovery of AKI as well as patient-centered outcomes among patients with IAH treated by APP target versus standard of care. To study renal injury and recovery and patient-centered outcomes among septic shock patients without IAH.
Time Frame
90 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult (age ≥ 18) Septic shock - identified as early as possible as evidenced by: Clinical diagnosis of sepsis defined as documented or suspected infection with the use of antibiotic administration OR Meets qSOFA (Quick Sequential Organ Failure Assessment) Criteria per the Sepsis-3 definitions: i. Respiratory rate ≥ 22/min ii. Altered mentation iii. Systolic blood pressure ≤ 100 mmHg AND c. Shock dependent on vasopressor therapy following initial 12-hour Resuscitation Period refractory to further volume expansion as assessed by clinical treatment team; this may be supported by either: i. Lack of blood pressure response following fluid bolus or passive leg raise ii. Hemodynamic data as available (e.g. PPV [positive pressure ventilation], SVV [stroke volume variation], echo, PAOP [pulmonary artery occlusion pressure], right-heart catheterization, etc.) Indication for a urinary bladder catheter (or one currently in place) Indication for an arterial line (or one currently in place at any site) FOR MONITORING PHASE OF STUDY (MONITORING GROUP) All of the above criteria for the Resuscitation and Observational Periods of the study Intra-abdominal pressure < 8 mmHg FOR INTERVENTION PHASE OF STUDY (APP VS MAP GROUPS) All of the above criteria for the Resuscitation and Observational Periods of the study Intra-abdominal pressure ≥ 8 mmHg Exclusion Criteria: Inability to receive a urinary bladder catheter Chronic suprapubic catheter in place Cirrhosis/end stage liver disease, including Child-Pugh class C Severe AKI [acute kidney injury] as defined by life-threatening electrolyte, acidemia, or other indication for imminent emergent dialysis needs within 12 hours of hospital admission Evidence of chronic renal failure stage 5 (including serum creatinine values consistent with CKD 5 [chronic kidney disease, stage 5] or dialysis dependence) in 12-months prior to enrollment Active gastrointestinal bleed likely causing/contributing to the hemodynamic instability Acute intra-abdominal trauma (including intraabdominal surgery within the prior 30 days) Acute pancreatitis with no established source of infection Treating physician deems aggressive care is unsuitable, or has decided to de-escalate care [Do Not Resuscitate (DNR) patients receiving standard care are still eligible] In the opinion of the treating attending physician the patient is unsuitable for the study for any legitimate reason including lack of equipoise, anticipated imminent significant deterioration, anticipated imminent recovery, incarceration, pre-existing medical or psychiatric condition that treating attending physician deems not appropriate for study, or interfering medications Known previous or concurrent enrollment in a treatment clinical trial that, in the opinion of the investigator, might interfere with the objectives/endpoints of this clinical trial Known contraindication to bladder pressure measurement Known pregnancy Suspected or known increased intracranial pressure requiring active neurosurgical consultation Cardiogenic shock requiring extracorporeal support Any requirement for chest compressions prior to enrollment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael J Connor, MD
Organizational Affiliation
Emory University School of Medicine, (404) 616-0184 michael.connor@emory.edu
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Luis Juncos, MD
Organizational Affiliation
CAVHS, Little Rock, AR 72205 (501) 257-1000 luis.juncos@va.gov
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Nithin Karakala, MD
Organizational Affiliation
University of Arkansas Medical Center, Little Rock, AR NKarakala@uams.edu
Official's Role
Principal Investigator
Facility Information:
Facility Name
Central Arkansas Veterans Healthcare System
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72205
Country
United States
Facility Name
University of Arkansas Medical Center
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72205
Country
United States
Facility Name
Grady Memorial Hospital
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30303
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Targeting Abdominal Perfusion Pressure in Septic Shock

We'll reach out to this number within 24 hrs